Fadraciclib
PreclinicalSmall molecule
Fadraciclib is one of 29 small molecule programs targeting Pediatric Cancer. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Pediatric Cancer
#DrugCompanyPhaseTrials
1Trisenox
CCephalon
Phase 2
Cytosar
TevaPhase 1
Bavencio
EMD SeronoPhase 1
Zanzalintinib
Merck & Co.Phase 1
Imfinzi
AstraZenecaPreclinical
Kisqali
NovartisPreclinical
Afinitor
NovartisPreclinical
Adavosertib
AstraZenecaPreclinical
Lynparza
AstraZenecaPreclinical
Camptosar
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelodysplastic Syndrome1 trial
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fadraciclib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCyclacel Pharmaceuticals, Inc.